版本:
中国

BRIEF-Durect presents data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)

April 24 Durect Corp

* Durect announces presentation of data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)

* DUR-928 was well tolerated in study

* Additional studies, including larger controlled trials, will be required to confirm findings

* Durect - reduction of biomarkers, results from animal, cell culture studies suggest potential therapeutic activity of DUR-928 in patients with liver disease Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐